Placental transfer of bromocriptine in an ex vivo human placental perfusion model. (3rd April 2019)

• Record Type: Journal Article
• Authors: Zheng, Qiaoling; Zhou, Qiong; Li, Juan; Tian, Yuqin; Huang, Hua; Yao, Qin; Wang, Jingjing; Zhang, Jun
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 32:Number 7(2019)
• Page Start: 1155
• Page End: 1159
• Publication Date: 2019-04-03
• Subjects: Bromocriptine -- placental transfer -- ex vivo human placental perfusion model -- pregnancy; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.1080/14767058.2017.1402000
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Purpose: To determine the rate and extent of the maternal–fetal transplacental passage of bromocriptine (BCT) in the dually perfused human placental model. Methods: Twenty term placentas were included in an ex vivo human placental perfusion experiment with a closed-circuit model. At the start of the perfusion, BCT at the concentration of 10 or 100 ng/ml along with 100 µg/ml antipyrine which used as a positive marker were added to the maternal reservoir. Samples were collected for the measurements of BCT and markers of placental viability both from the maternal reservoir and fetal reservoir throughout the perfusion which lasted for 3 h. Determination of BCT was carried out with liquid chromatography–tandem mass spectrometry. Results: At the end of the study, the concentration in the fetal compartment was 0.82 ± 0.32 ng/ml in the low concentration group and 5.02 ± 0.97 ng/ml in the high concentration group with a fetal transfer rate of 6.13 ± 1.94% and 5.46 ± 0.87%, respectively. Conclusion: These data showed that only trace amount of BCT could transport across the human placenta in vitro which suggested that fetal exposure to maternally administered BCT may be insignificant. More additional studies are required to explore the safety of BCT administrated in pregnancy.